Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TachoSil in Pancreaticojejunostomy
NCT03269955Phase 4Unknown
- Sponsor
- Asan Medical Center
- Start
- Feb 2017
- Primary completion
- May 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of tachosil in pancreatic neoplasm and periampullary cancer (2 arms), sponsored by Asan Medical Center. Primary endpoints: Incidence of pancreatic fistula at 3 days and Incidence of clinically relevant pancreatic fistula at 5 days. Status: unknown.
02
Drugs
tachosil
03
Conditions
pancreatic neoplasmperiampullary cancer
Beyond the preview
Go deeper on NCT03269955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03269955.